2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 988

Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis
Abstract Number: 2389

Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed
Abstract Number: 2337

Treat to Target Is Not Linked to Best Myocardial Strain Indices: Is There Really a Myocardial Dysfunction Directly Associated with Disease Activity?
Abstract Number: 1862

Treat to Target Opportunities – Design, Testing, and Adoption of a Novel EHR-Integrated Electronic System to Engage Rheumatologists and Capture Decision Making
Abstract Number: 414

Treat-to-Target Approach in the Management of Elderly Rheumatoid Arthritis Patients
Abstract Number: 336

Treating Gout to Target Entails Renoprotective Effect in Patients with Moderate Chronic Kidney Disease
Abstract Number: 388

Treating Statin-induced Anti-HMGCR Myopathy with Normal Muscle Strength: A New Window of Opportunity
Abstract Number: 2830

Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study
Abstract Number: 763

Treatment Efficacy Evaluation of Leflunomide by Regulating Macrophages in Takayasu Arteritis
Abstract Number: 2383

Treatment for Rheumatoid Arthritis After Methotrexate-associated Lymphoproliferative Disorder Developed
Abstract Number: 2340

Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Abstract Number: 941

Treatment of Lupus Nephritis with anti-CD20 Followed by Anti-BAFF: Impact on B Cell Reconstitution, B Cell Subsets, and Autoreactivity
Abstract Number: 69

Treatment of Lupus-prone MRL-lpr Mice with the Mitochondrial Antioxidant MitoQ
Abstract Number: 2520

Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial
Abstract Number: 953

Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].